Goldman Sachs
JNP

Goldman Sachs’s Juniper Pharmaceuticals, Inc. Common Stock JNP Stock Holding History

Goldman Sachs’s Portfolio JNP Stock Details JNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-25,165
Closed -$255K – 6249
2018
Q1 		$255K Buy
+25,165
New +$211K ﹤0.01% 4873
2017
Q3 		– Sell
-21,735
Closed -$110K – 7020
2017
Q2 		$110K Buy
21,735
+715
+3% +$3.2K ﹤0.01% 6079
2017
Q1 		$100K Buy
+21,020
New +$106K ﹤0.01% 6061

Other funds holding JNP

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
JAM
JW Asset Management Miami Beach, Florida $244M AUM 71.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
AG
Algert Global San Francisco, California $6.65B AUM 53.68% 1-Year Est. Return
MERSOM
Municipal Employees' Retirement System of Michigan Lansing, Michigan $8.81B AUM 10.88% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Goldman Sachs's JNP Position: Q2 2018 in Review

Goldman Sachs sold out of Juniper Pharmaceuticals, Inc. Common Stock (JNP) in Q2 2018, closing a stake of 25,165 shares — an estimated $255K sold.

Goldman Sachs first reported a position in JNP in Q1 2017 and held it in 3 quarters. The position peaked at $255K in Q1 2018. 48 funds tracked by Wall St. Rank hold JNP as of Q2 2018.

  • Goldman Sachs reported no remaining Juniper Pharmaceuticals, Inc. Common Stock position as of Q2 2018 after selling out during the quarter.
  • Goldman Sachs sold 25,165 Juniper Pharmaceuticals, Inc. Common Stock shares in Q2 2018, an estimated $255K.
  • Goldman Sachs first reported a position in Juniper Pharmaceuticals, Inc. Common Stock in Q1 2017 and held it in 3 quarters.
  • Goldman Sachs's Juniper Pharmaceuticals, Inc. Common Stock position peaked at $255K in Q1 2018.
  • 48 funds tracked by Wall St. Rank held Juniper Pharmaceuticals, Inc. Common Stock as of Q2 2018.

Based on Goldman Sachs's 13F filing for Q2 2018, filed 14 Aug 2018.